Low-Grade Glioma Industry Report 2025: Market Overview, Trends & Competitive Landscape

29 Apr, 2025

The Low-Grade Glioma Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.

What are the Historical Growth Trends in the Low-Grade Glioma Market?

The market size for low-grade glioma has seen solid growth over the past few years. The market will increase from $1.39 billion in 2024 to $1.48 billion in 2025, delivering a compound annual growth rate (CAGR) of 6.1%.

What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Low-Grade Glioma Industry?

The Low-Grade Glioma Global Market Report 2025 market is projected to reach a size of $1.86 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 5.9%.

Download Your Free Sample of the 2025 Low-Grade Glioma Market Report and Uncover Key Trends Now!

What are the Key Growth Drivers Fueling the Low-Grade Glioma Market?

The key drivers in the low-grade glioma market are:

• Rising aging population fueling the demand
• Boost in healthcare expenditure globally
• Increasing prevalence of brain tumors
• Growing government initiatives for low-grade glioma treatments

Global Market Segmentation: Identifying Major Low-Grade Glioma Industry Segments

The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Pre-order the 2025 Low-Grade Glioma Global Market Report for Fast Delivery & Comprehensive Insights!

What are the emerging Trends Shaping the Future of the Low-Grade Glioma Market?

The key trends in the low-grade glioma market are:

• Advancements in imaging technologies are shaping the future of the low-grade glioma market.
• Development of radiation therapies is an emerging trend in the market.
• The introduction of chemotherapy regimens is a significant factor in the evolving market.
• The integration of immunotherapy and expanding clinical trials are key trends observed in the market.

Who Are the Top Competitors & Leading Players in the Low-Grade Glioma Market?

Major players in the low-grade glioma market are:

• McKesson Corporation
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Daiichi Sankyo Company Limited
• Ipsen S.A.
• BeiGene Ltd.
• NovoCure Limited
• Les Laboratoires Servier
• Day One Biopharmaceuticals Inc.
• CStone Pharmaceuticals Co. Ltd.
• AnHeart Therapeutics Inc.
• Apollomics Inc.
• Agios Pharmaceuticals Inc.
• BioMed Valley Discoveries Inc.
• Avistone Biotechnology Co. Ltd.
• NextSource Biotechnology LLC
• Sunesis Pharmaceuticals Inc.

Regional Dominance: Which Area Leads the Global Template Market?

North America was the largest region in the low-grade glioma market in 2024